FDA Gives Jerini AG Angioedema Drug Priority Review

NEW YORK (Reuters) - German biotech firm Jerini AG said on Friday that U.S. regulators at the Food and Drug Administration have granted priority review of its Icatibant drug for the treatment of skin-swelling disease hereditary angioedema.